To make the best possible decisions about breast cancer treatment, you and your doctor need to know all the details of your unique medical situation, including the "personality" of the cancer as described in your pathology report.
A large group of cancer experts from around the world met in Europe and created new guidelines for treating early-stage breast cancer. The guidelines recommend that:
should be based on the characteristics of each individual cancer being treated.
Called the 2009 St. Gallen International Expert Consensus, the meeting was attended by about 5,000 breast cancer experts. A group of 43 experts wrote the guidelines based on discussions among the entire group.
Every breast cancer is different. A breast cancer's personality is based on its:
The new guidelines for treating early-stage breast cancer are based on the best scientific knowledge available right now.
The guidelines recommend:
Hormonal therapy, which can reduce the risk of early-stage breast cancer coming back, should be used to treat all early-stage breast cancers with any detectable level of estrogen receptors. Tamoxifen and the aromatase inhibitors are examples of hormonal therapy medicines.
Herceptin (chemical name: trastuzumab), a targeted therapy, which can reduce the risk of early-stage breast cancer coming back, should be used to treat only breast cancers that are HER2-positive. Chemotherapy, either before or during Herceptin treatment, also is an important treatment for HER2-positive breast cancer.
Chemotherapy, which can reduce the risk of early-stage breast cancer coming back, always should be used to treat triple-negative early-stage breast cancer. Triple-negative breast cancer is cancer that is estrogen-receptor-negative, progesterone-receptor-negative, and HER2-negative. Hormonal therapy medicines and Herceptin usually don't work on triple-negative breast cancer.
The new guidelines also point out that hormone receptor and HER2 test results must be accurate and reliable.
The panel of experts couldn't agree on whether gene assay tests, such as the Oncotype DX test, were helpful in making treatment decisions. The Oncotype DX test looks at the behavior of a specific group of genes in breast cancer cells. The genes' activity can affect how likely a cancer is to respond to treatment. The Oncotype DX test is used on estrogen-receptor-positive breast cancers and can help doctors decide if the cancer is likely to come back; if so, chemotherapy may be recommended. Even though the expert panel's new treatment guidelines for early-stage breast cancer don't recommend using the Oncotype DX test, many doctors believe results from the Oncotype DX test can help decide which hormone-receptor-positive early-stage breast cancers also need to be treated with chemotherapy.
If you've been diagnosed with early-stage breast cancer and are deciding on treatment, ask your doctor to go over ALL the information about the breast cancer with you. This should include your pathology report. Then, together, you can make the best treatment decisions for your specific situation.
The Breastcancer.org Planning Your Treatment section has more information on treatment options and how you and your doctor will choose the best ones for you.
HOUSTON, June 17 (MedPage Today) -- In an international consensus statement described as practice-changing, new treatment guidelines for early-stage breast cancer call for use of systemic therapies on the basis of individual tumor characteristics.
Treatment decisions should focus on the scientific justification for using endocrine therapy, anti-HER2 treatment, and chemotherapy, authors of the 2009 St Gallen International Expert Consensus concluded in guidelines published online in Annals of Oncology.
Though recognizing the heterogeneous nature of breast cancer, the consensus recommendations call for development of a personalized treatment plan for each patient.
The guidelines include a new treatment algorithm based on advances in knowledge about how to match therapy with tumor characteristics to achieve the best outcomes.
"Because these decisions are based on quite separate criteria, previous attempts to produce a single-risk categorization and a separate therapy recommendation are no longer considered appropriate," the authors said.
In a prepared statement, panel member Richard Gelber, MD, of Harvard and Dana-Farber Cancer Institute in Boston, said the consensus "further refines the treatment algorithm by identifying 'thresholds for indication' of each type of systemic treatment modality based on criteria specific to each modality.
"We expect the refined algorithm to change clinical practice because it clarifies the indications for each treatment modality available today."
Knowing the specific tumor characteristics is essential for deciding which treatment or combination offers a patient the best chance for success. Consistent with that approach to decision making, the panel set forth some general principles for treatment selection:
The corollary to recommendations about endocrine and anti-HER2 therapy is that "ER and HER2 must be reliably and accurately measured."
Any method of ER staining is acceptable. However, the panel recommended adherence to American Society of Clinical Oncology/College of American Pathologists guidelines for assessing HER2 status.
The consensus guidelines include summaries of the state of knowledge in disciplines relevant to early breast cancer, as presented and discussed at the consensus meeting.
Examples include chemoprevention with selective estrogen receptor modulators, the role of stem cells in breast cancer, implications of circulating tumor cells, angiogenesis, pharmacogenetics, novel imaging techniques, and novel systemic therapies.
Although focused on systemic therapy, the consensus panel expressed support for continued refinement of surgical and radiation techniques to ensure the best possible outcome with the least possible morbidity.
The panel was circumspect on use of genetic testing in making treatment decisions, reflecting the controversy surrounding the issue.
Panelists avoided the term "gene assay," and said genetic testing might have some value if doubt remains after reviewing all other factors and a test is readily available.
"There was clearly a division of opinion, largely on geographic grounds," panelist Alan Coates, MD, of the University of Sydney, Australia, said in an interview.
"Many of the U.S. representatives and some Europeans were keen to say these tests are now established sufficiently, and that they are not only useful for prognosis, but also helpful to decide whether it will be valuable at prediction of the additional benefit of chemotherapy.
"Others felt that because two of the principal trials investigating markers for exactly that purpose have yet to report any results, as such, it is premature to make that conclusion. I must say I tend toward the second point of view, but there was a clear division on the panel."
The 43-member panel drafted the recommendations in March at the 11th St Gallen (Switzerland) consensus meeting, which had a total attendance of almost 5,000.
The published consensus did not include disclosures of potential conflicts of interest.
Primary source: Annals of Oncology Source reference: Goldhirsch A, et al "Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009" Ann Oncol 2009; DOI:10.1093/annonc/mdp322.
Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003
Learn more about our commitment to your privacy
© 2009 Breastcancer.org - All rights reserved.
Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.
_tcm8-332386.jpg "wellness_dvd_promo")